Salim Hussein Hassan, Mohammad Y Alshahrani, Raed Obaid Saleh, Bahira Abdulrazzaq Mohammed, Abhinav Kumar, Sami G Almalki, Adnan Taan Alkhafaji, Pallavi Ghildiyal, Ahmed Read Al-Tameemi, Ahmed Elawady
Chimeric Antigen Receptor (CAR) based therapies are becoming increasingly important in treating patients. CAR-T cells have been shown to be highly effective in the treatment of hematological malignancies. However, harmful therapeutic barriers have been identified, such as the potential for graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndrome (CRS). As a result, CAR NK-cell therapy is expected to be a new therapeutic option. NK cells act as cytotoxic lymphocytes, supporting the innate immune response against autoimmune diseases and cancer cells by precisely detecting and eliminating malignant cells...
April 24, 2024: Medical Oncology